ArticleJournal of diabetes and metabolic disorders2025
Metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes mellitus and diabetic foot ulcers: prevalence and associated factors.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-cell Sequencing and Machine Learning Identify Amino Acid Metabolism-related Biomarkers and Regulatory Mechanisms in Diabetic Foot Ulcers.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent among individuals with overweight, obesity, and type 2 diabetes mellitus (T2DM). Diabetic foot ulcers (DFUs) represent a severe complication of T2DM, but the prevalence of MASLD in this specific population remains unexplored. This study investigated the potential influence of DFU on MASLD incidence in T2DM. Methods: This study included 100 individuals with T2DM and DFUs. MASLD was assessed via liver ultrasound. Demographic data, laboratory results, and body mass index (BMI) were recorded. Participants were stratified into three BMI categories (≤ 25, 25-30, and ≥ 30 kg/m²) for comparative analysis. Results: The overall MASLD frequency was 39%, with no significant difference between genders (42.3% in males vs. 35.4% in females; Conclusions: This study offers novel insights into MASLD prevalence among individuals with T2DM and DFU, suggesting a potential association between lower BMI and reduced MASLD incidence. However, MASLD development is multifactorial. Further research is needed to investigate the lower BMI levels observed and elucidate the complex interplay of factors influencing MASLD development in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.